Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 6/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Veledimex SCHEMBL2681772 | 1.00 | ABCB1 (0.52) | ABCB1TAS1R3TAS1R1CYP3A4NPC1 | |
| Veledimex SCHEMBL29684354 | 1.00 | ABCB1 (0.52) | ABCB1TAS1R3TAS1R1CYP3A4NPC1 | |
| Veledimex SCHEMBL29684650 | 1.00 | ABCB1 (0.52) | ABCB1TAS1R3TAS1R1CYP3A4NPC1 | |
| Veledimex SCHEMBL2323179 | 1.00 | ABCB1 (0.52) | ABCB1TAS1R3TAS1R1CYP3A4NPC1 | |
| Veledimex SCHEMBL18653545 | 0.99 | ABCB1 (0.51) | ABCB1TAS1R3TAS1R1CYP3A4NPC1 | |
| SCHEMBL29685086 | 0.93 | ABCB1 (0.45) | ABCB1TAS1R3TAS1R1NPC1RAB9A | |
| SCHEMBL668921 | 0.93 | ABCB1 (0.45) | ABCB1TAS1R3TAS1R1NPC1RAB9A | |
| SCHEMBL28000981 | 0.93 | ABCB1 (0.47) | ABCB1TAS1R3TAS1R1CYP3A4NPC1 | |
| SCHEMBL667995 | 0.93 | ABCB1 (0.53) | ABCB1CYP3A4NPC1RAB9A | |
| SCHEMBL29684628 | 0.93 | ABCB1 (0.53) | ABCB1CYP3A4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118987016-A | Application of antisense oligonucleotide in preparing medicament for treating glioma | 北京悦康科创医药科技股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-118987015-A | Application of antisense oligonucleotide in preparation of medicine for treating breast cancer | 北京悦康科创医药科技股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2024077255-A1 | METHODS AND MATERIALS FOR THE CONDITIONAL HEPATIC EXPRESSION OF TRANSGENES IN MAMMALIAN BIOINCUBATORS | CYTOTHERYX, INC. (US) | 2024-04-11 | — | — | WO | claimed |
| CN-110770249-B | Delivery of autologous cells comprising matrix metalloproteinases for the treatment of scleroderma | 英特瑞克斯顿股份有限公司 | 2024-03-29 | — | — | CN | claimed |
| US-20230399370-A1 | METHODS OF TREATING GLIOBLASTOMA | ALAUNOS THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | US | claimed |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | claimed |
| EP-4061485-A1 | METHODS OF TREATING GLIOBLASTOMA | Alaunos Therapeutics, Inc. (US) | 2022-09-28 | — | — | EP | claimed |
| EP-3357904-B1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | PRECIGEN INC (US) | 2022-07-06 | — | — | EP | claimed |
| EP-3813854-A1 | IN VIVO CONTROLLED COMBINATION THERAPY FOR TREATMENT OF CANCER | Precigen, Inc. (US) | 2021-05-05 | — | — | EP | claimed |
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2020-08-27 | — | — | US | claimed |
| US-8946294-B2 | Crystalline diacylhydrazine and the use thereof | INTREXON CORPORATION (US) | 2015-02-03 | — | — | US | claimed |
| EP-2207874-B1 | ENGINEERED DENDRITIC CELLS AND USES FOR THE TREATMENT OF CANCER | INTREXON CORP (US) | 2014-12-03 | — | — | EP | claimed |
| US-8884060-B2 | Process of preparing chiral diacylhydrazine ligands | INTREXON CORPORATION (US) | 2014-11-11 | — | — | US | claimed |
| EP-2751072-A1 | CRYSTALLINE DIACYLHYDRAZINE AND THE USE THEREOF | Intrexon Corporation (US) | 2014-07-09 | — | — | EP | claimed |
| EP-2674483-A1 | Engineered dendritic cells and uses for the treatment of cancer | Intrexon Corporation (US) | 2013-12-18 | — | — | EP | claimed |
| US-20130079413-A1 | Crystalline Diacylhydrazine and the Use Thereof | INTREXON CORPORATION (US) | 2013-03-28 | — | — | US | claimed |
| WO-2013036758-A1 | CRYSTALLINE DIACYLHYDRAZINE AND THE USE THEREOF | INTREXON CORPORATION (US) | 2013-03-14 | — | — | WO | claimed |
| US-20120116090-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2012-05-10 | — | — | US | claimed |
| US-8076517-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2011-12-13 | — | — | US | claimed |
| US-20090163592-A1 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | ABCB1 525/4885TAS1R3 4751/4885TAS1R1 4683/4885 |
| US-20090163592-A1 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, CRYZ, TCF12 | ABCB1 692/4885TAS1R3 3889/4885TAS1R1 4166/4885 |
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | ABCB1 692/4885TAS1R3 3889/4885TAS1R1 4166/4885 |
| US-20230399370-A1 | METHODS OF TREATING GLIOBLASTOMA | GMFG, IL6ST, IL2 | ABCB1 4002/4885TAS1R3 2479/4885TAS1R1 2753/4885 |
| US-20120116090-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | ABCB1 692/4885TAS1R3 3889/4885TAS1R1 4166/4885 |
| US-20130079413-A1 | Crystalline Diacylhydrazine and the Use Thereof | RCC1, BBC3, MITF | ABCB1 1029/4885TAS1R3 3589/4885TAS1R1 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.